Executive Summary

Molecular diagnostics firm Curetis has appointed Achim Plum to the newly-created role of chief commercial officer. Dr Plum’s in vitro diagnostics experience includes eight years at Epigenomics, after which he joined Siemens where he was focused on assessing and developing novel approaches to the IVD market. At Curetis, Dr Plum will oversee all commercial activities, including international sales, business development, marketing and medical affairs. The German firm, based in Holzgerlingen, has CE marked its Unyvero multiplexing platform and is marketing it in Europe, the Middle East and other countries outside the EU. The technology is currently being trialled in the US with the aim of getting FDA approval.